Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Receives Average Recommendation of “Buy” from Analysts

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) has received an average rating of “Buy” from the six research firms that are presently covering the firm, MarketBeat.com reports. Four equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $11.25.

A number of equities research analysts have recently commented on RVPH shares. Roth Capital raised Reviva Pharmaceuticals to a “strong-buy” rating in a research report on Friday, January 10th. Roth Mkm initiated coverage on shares of Reviva Pharmaceuticals in a report on Friday, January 10th. They set a “buy” rating and a $7.00 target price on the stock. Maxim Group upgraded shares of Reviva Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 price target for the company in a report on Friday, January 10th. Finally, EF Hutton Acquisition Co. I upgraded shares of Reviva Pharmaceuticals to a “strong-buy” rating in a report on Monday, September 23rd.

Hedge Funds Weigh In On Reviva Pharmaceuticals

An institutional investor recently raised its position in Reviva Pharmaceuticals stock. Geode Capital Management LLC lifted its holdings in Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) by 17.9% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 278,496 shares of the company’s stock after purchasing an additional 42,376 shares during the quarter. Geode Capital Management LLC owned 0.83% of Reviva Pharmaceuticals worth $401,000 as of its most recent SEC filing. 63.18% of the stock is owned by hedge funds and other institutional investors.

Reviva Pharmaceuticals Stock Down 0.6 %

Shares of Reviva Pharmaceuticals stock opened at $1.77 on Friday. Reviva Pharmaceuticals has a 12 month low of $0.60 and a 12 month high of $4.83. The stock’s fifty day simple moving average is $1.64 and its 200 day simple moving average is $1.31.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.